From Dealroom · · 30s
Specific Biologics Raises $35M for ALS Gene Editing
Specific Biologics secures $35M Series A to advance ALS gene editing into human trials.
In brief
Specific Biologics secures $35M Series A to advance ALS gene editing into human trials. Specific Biologics raised $35 million for its ALS gene-editing therapy to enter clinical trials. Originally reported by Dealroom.
Series A Funding
Specific Biologics closed an oversubscribed US$35 million Series A to advance its lead gene-editing candidate toward human trials.
Investors
Hatteras Venture Partners led the round, joined by Lumira Ventures and adMare BioInnovations.
Endgame
The company develops precision gene-editing therapies for serious genetic diseases using its Dualase platform.
The takeaway
Specific Biologics raised $35 million for its ALS gene-editing therapy to enter clinical trials.
